Orion Oyj

ORNBV

FI0009014377

Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 11:29:46 2024-04-24 am EDT			5-day change	1st Jan Change
33.1 ^EUR	-0.06%		+2.35%	-15.71%

Mar. 22	Orion to Continue Reviewing Outsources Options for Finnish Plant as Change Negotiations Complete	MT
Mar. 22	Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024	CI

Orion Corporation Announces Composition of the Nomination Committee

April 27, 2021 at 11:20 am EDT

The Board of Directors of Orion Corporation has elected the persons to the Nomination Committee of the company: Annika Ekman; Erkki Etola; Petteri Karttunen; Matti Kavetvuo; Timo Maasilta; Heikki Westerlund; and Jukka Ylppö. Heikki Westerlund was elected Chairman of the Committee.

Latest news about Orion Oyj

Orion to Continue Reviewing Outsources Options for Finnish Plant as Change Negotiations Complete	Mar. 22	MT
Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024	Mar. 22	CI
Orion Corporation Announces Board and Committee Appointment	Mar. 20	CI
Orion Corporation Approves Board Appointments	Mar. 20	CI
Orion Corporation Approves Dividend for the Financial Year Ended 31 December 2023, Payable on 3 April 2024 and 23 October 2024	Mar. 20	CI
Orion Unveils Partnership with Save the Children Finland	Feb. 22	MT
Orion Explores Potential Outsourcing of Kuopio Plant’s Production Operations	Feb. 19	MT
Transcript : Orion Oyj, 2023 Earnings Call, Feb 13, 2024	Feb. 13
Orion Provides FY24 Sales, Operating Profit Guidance	Feb. 13	MT
Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member	Feb. 13	CI
Orion Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Orion Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Orion Oyj Proposes Dividend for the Financial Year Ended on 31 December 2023, Payable on 3 April 2024 and 23 October 2024	Feb. 13	CI
Orion Oyj Provides Earnings Guidance for the Year 2024	Feb. 13	CI
Orion Inks License Deal With Newel Health for Digital Therapeutic	Jan. 29	MT
Orion Corporation and Newel Health Enter into Licensing Agreement for Digital Therapeutic(DTx) ODD-403 (?Rohkea?) in pain	Jan. 29	CI
Orion CFO to Step Down, Successor Appointed	Jan. 23	MT
Orion Oyj Announces CFO Changes	Jan. 23	CI
Orion Flags EUR31 Million Gain in FY23 from Pension Fund’s Insurance Portfolio Transfer	Jan. 11	MT
Orion, Glykos Finland Tie Up for Development of Antibody-drug Conjugates	Jan. 08	MT
Orion Corporation and Glykos Finland Oy Announce Research Collaboration and Licensing Agreement to Develop Next-Generation Adcs	Jan. 08	CI
Orion Starts Two Late-stage Studies for Investigational Prostate Cancer Therapy	Jan. 05	MT
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe	Dec. 14	MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe	Dec. 13	CI
Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database	Nov. 21	CI

Chart Orion Oyj

Duration

Period

More charts

Company Profile

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Sector

Pharmaceuticals

Calendar

05:00am - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Orion Oyj

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

33.1 EUR

Average target price

39.2 EUR

Spread / Average Target

+18.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION OYJ	-15.71%	5B
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Orion Oyj

Equities

ORNBV

FI0009014377

Pharmaceuticals

Orion Corporation Announces Composition of the Nomination Committee

EPS Revisions